Heart Failure with Preserved Ejection Fraction in Women

Heart Failure Clinics

Volumn 15, Issue 1, 2019, Pages 9-18

  Tibrewala, Anjan ^a   Yancy, Clyde W ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Diastolic heart failure; Heart failure with preserved ejection fraction; Sex differences; Women

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; SEX HORMONE; SPIRONOLACTONE;

AGE; COMORBIDITY; DIABETES MELLITUS; EXERCISE; FEMALE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MORTALITY RATE; OBESITY; PERSONALIZED MEDICINE; QUALITY OF LIFE; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE; HEART FAILURE; HEART STROKE VOLUME; NEEDS ASSESSMENT; PATHOPHYSIOLOGY; PATIENT CARE; PREVALENCE; PROCEDURES; RISK FACTOR; STANDARDS; WOMEN'S HEALTH;

FEMALE; HEART FAILURE; HUMANS; NEEDS ASSESSMENT; PATIENT CARE MANAGEMENT; PREVALENCE; RISK FACTORS; STROKE VOLUME; WOMEN'S HEALTH;

EID: 85056585645     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2018.08.002     Document Type: Review

References (45)

1. Benjamin, E.J., Virani, S.S., Callaway, C.W., et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation 137:12 (2018), e67–e492.
2. Steinberg, B.A., Zhao, X., Heidenreich, P.A., et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 126:1 (2012), 65–75.
3. Owan, T.E., Redfield, M.M., Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 47:5 (2005), 320–332.
4. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136:6 (2017), e137–e161.
5. Ho, J.E., Enserro, D., Brouwers, F.P., et al. Predicting heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes. Circ Heart Fail, 9(6), 2016 [pii:e003116].
6. Eaton, C.B., Pettinger, M., Rossouw, J., et al. Risk factors for incident hospitalized heart failure with preserved versus reduced ejection fraction in a multiracial cohort of postmenopausal women. Circ Heart Fail, 9(10), 2016 [pii:e002883].
7. Pandey, A., Omar, W., Ayers, C., et al. Sex and race differences in lifetime risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Circulation 137:17 (2018), 1814–1823.
8. Borlaug, B.A., Heart failure with preserved and reduced ejection fraction: different risk profiles for different diseases. Eur Heart J 34:19 (2013), 1393–1395.
9. Cheng, S., Xanthakis, V., Sullivan, L.M., et al. Correlates of echocardiographic indices of cardiac remodeling over the adult life course: longitudinal observations from the Framingham Heart Study. Circulation 122:6 (2010), 570–578.
10. Gori, M., Lam, C.S., Gupta, D.K., et al. Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. Eur J Heart Fail 16:5 (2014), 535–542.
11. Merz, A.A., Cheng, S., Sex differences in cardiovascular ageing. Heart 102:11 (2016), 825–831.
12. Gupta, D.K., de Lemos, J.A., Ayers, C.R., et al. Racial differences in natriuretic peptide levels: the Dallas Heart Study. JACC Heart Fail 3:7 (2015), 513–519.
13. Chamberlain, A.M., St Sauver, J.L., Gerber, Y., et al. Multimorbidity in heart failure: a community perspective. Am J Med 128:1 (2015), 38–45.
14. Saiki, H., Petersen, I.A., Scott, C.G., et al. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. Circulation 135:15 (2017), 1388–1396.
15. Sharma, K., Al Rifai, M., Ahmed, H.M., et al. Usefulness of coronary artery calcium to predict heart failure with preserved ejection fraction in men versus women (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol 120:10 (2017), 1847–1853.
16. Lam, C.S., Lyass, A., Kraigher-Krainer, E., et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation 124:1 (2011), 24–30.
17. Paulus, W.J., Tschope, C., A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62:4 (2013), 263–271.
18. Shah, S.J., Kitzman, D.W., Borlaug, B.A., et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation 134 (2016), 73–90.
19. Hall, P.S., Nah, G., Howard, B.V., et al. Reproductive factors and incidence of heart failure hospitalization in the women's health initiative. J Am Coll Cardiol 69:20 (2017), 2517–2526.
20. Florijn, B.W., Bijkerk, R., van der Veer, E.P., et al. Gender and cardiovascular disease: are sex-biased microRNA networks a driving force behind heart failure with preserved ejection fraction in women?. Cardiovasc Res 114:2 (2018), 210–225.
21. Zhao, Z., Wang, H., Jessup, J.A., et al. Role of estrogen in diastolic dysfunction. Am J Physiol Heart Circ Physiol 306:5 (2014), H628–H640.
22. Ebong, I.A., Watson, K.E., Goff, D.C. Jr., et al. Age at menopause and incident heart failure: the Multi-Ethnic Study of Atherosclerosis. Menopause 21:6 (2014), 585–591.
23. Shah, S.J., Katz, D.H., Selvaraj, S., et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131:3 (2015), 269–279.
24. Kao, D.P., Lewsey, J.D., Anand, I.S., et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail 17:9 (2015), 925–935.
25. Hoekstra, T., Lesman-Leegte, I., van Veldhuisen, D.J., et al. Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction. Eur J Heart Fail 13:9 (2011), 1013–1018.
26. Deswal, A., Bozkurt, B., Comparison of morbidity in women versus men with heart failure and preserved ejection fraction. Am J Cardiol 97:8 (2006), 1228–1231.
27. Chang, P.P., Chambless, L.E., Shahar, E., et al. Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the Atherosclerosis Risk in Communities Study). Am J Cardiol 113:3 (2014), 504–510.
28. Lam, C.S., Carson, P.E., Anand, I.S., et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 5:5 (2012), 571–578.
29. O'Meara, E., Clayton, T., McEntegart, M.B., et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 115:24 (2007), 3111–3120.
30. Nichols, G.A., Reynolds, K., Kimes, T.M., et al. Comparison of risk of re-hospitalization, all-cause mortality, and medical care resource utilization in patients with heart failure and preserved versus reduced ejection fraction. Am J Cardiol 116:7 (2015), 1088–1092.
31. O'Neal, W.T., Sandesara, P., Hammadah, M., et al. Gender differences in the risk of adverse outcomes in patients with atrial fibrillation and heart failure with preserved ejection fraction. Am J Cardiol 119:11 (2017), 1785–1790.
32. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 33:14 (2012), 1750–1757.
33. Hsich, E.M., Grau-Sepulveda, M.V., Hernandez, A.F., et al. Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. Am Heart J 163:3 (2012), 430–437 437.e1-3.
34. Senni, M., Paulus, W.J., Gavazzi, A., et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J 35:40 (2014), 2797–2815.
35. Kitzman, D.W., Brubaker, P., Morgan, T., et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical Trial. JAMA 315:1 (2016), 36–46.
36. Hummel, S.L., Seymour, E.M., Brook, R.D., et al. Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction. Hypertension 60:5 (2012), 1200–1206.
37. Hummel, S.L., Seymour, E.M., Brook, R.D., et al. Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction. Circ Heart Fail 6:6 (2013), 1165–1171.
38. Lund, L.H., Benson, L., Dahlstrom, U., et al. Association between use of beta-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA 312:19 (2014), 2008–2018.
39. Yusuf, S., Pfeffer, M.A., Swedberg, K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362:9386 (2003), 777–781.
40. Lund, L.H., Benson, L., Dahlstrom, U., et al. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 308:20 (2012), 2108–2117.
41. Pfeffer, M.A., Claggett, B., Assmann, S.F., et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131:1 (2015), 34–42.
42. Kao, D.P., Flint, K.M., Merrill, M., Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. Eur J Heart Fail, 19(Suppl. S1), 2017, 530.
43. Lytvyn, Y., Bjornstad, P., Udell, J.A., et al. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 136:17 (2017), 1643–1658.
44. Fitchett, D., Zinman, B., Wanner, C., et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 37:19 (2016), 1526–1534.
45. Solomon, S.D., Zile, M., Pieske, B., et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380:9851 (2012), 1387–1395.